MedTrace Logo

ASPIRE I: Supporting Antibiotic Stewardship in Primary Care Via POCT

NCT06912022 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2025-04-04

No results posted yet for this study

Summary

The ASPIRE study is an uncontrolled observational feasibility study, and a collaboration between the University of South Wales and Cwm Taf Morgannwg University Health Board (CTMUHB). The study is based at Ysbyty Cwm Rhondda (YCR) and Keir Hardy Primary Care (KHPC) centres, where participant recruitment will take place. Study participants will be invited to provide capillary blood samples (via finger prick sampling) for testing. The principal investigators are Dr Aled Davies at YCR and Dr Shyama Velupillai at KHPC. Upon clinical assessment, and after provision of consent, participants will undergo an ARI (acute respiratory infection) POC assay. This is a dual marker immunoassay designed to detect raised levels of C-reactive protein and MxA in capillary blood. The assay uses the sensitivity of CRP and specify of MxA to aid in the differentiation of ARI's in Primary Care.

The POC assay results will be compared to the participants clinical outcomes and the physician directed treatment pathway via reviewing medical records and by contacting the patient from 14 days after their visit.

Conditions

  • Acute Respiratory Infection

Interventions

DEVICE

FebriDx Device

Patients suspected of an acute respiratory infection were tested using the FebriDx POC assay.

Sponsors & Collaborators

  • Cwm Taf University Health Board (NHS)

    collaborator OTHER_GOV

  • University of South Wales

    lead OTHER

Principal Investigators

  • Prof Mark Williams, PhD · Chief Investigator University of South Wales

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-12
Primary Completion
2022-12-05
Completion
2023-01-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06912022 on ClinicalTrials.gov